提醒

Standard BioTools Inc. (LAB)

NasdaqGS: LAB · 即時價格 · USD

0.78

-0.01 (-1.27%)

收盤時： Aug 12, 2026, 11:56 AM

-1.27% (1D)

買價	0.55
市值	308.02M
營收 (ttm)	84.6M
淨利（ttm）	-53.93M
貝塔	n/a
EPS (ttm)	-0.13
本益比（ttm）	n/a
正向 PE	-78.46
P/B (ttm)	0.57
P/S (ttm)	3.64
Earnings Date	Nov 3, 2026

賣價	1
成交量	238,791
20 日平均成交量	3,434,572
打開	0.77
上一頁關閉	0.79
日間範圍	0.77 - 0.79
52 週範圍	0.70 - 1.72
分析師	Hold
目標價	1.35 (73.08%)
股利	n/a
Ex-股利日期	n/a

關於LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses....

[閱讀更多]

工業 Medical Devices

部門 Healthcare

IPO 日期 Feb 10, 2011

員工 385

證券交易所 NasdaqGS

股票代號 LAB

網站 https://www.standardbio.com

完整的公司簡介

財務表現

Standard BioTools 在 2025 年的營收為 85.33M，較前一年的 91.01M 減少 -6.24%。淨利為 -74.9M，較前期減少 -46.07%。

財務報表

分析師預測

根據1 分析師評等，LAB股票的平均評等為「Hold」。 12個月股價預測為1.35，與最新價格相比為上漲空間的73.08%。

股票預測

獲利驚喜

Standard BioTools 已於 Aug 5, 2026 公布季度財報：

營收的 $20.1M 錯過估計 $0, 與 -7.62% YoY 下降.

EPS 的 -0.06 錯過估計 -0.03, 與 -50.00% YoY 下降.

下次財報發布

Standard BioTools Inc. 定於發布財報 Nov 3, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

2 週前 · MT Newswires

Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences

Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multi

2 月前 · BioPharma Dive

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

3 月前 · Zacks

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4 月前 · Insider Monkey

Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why

Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock re...

5 月前 · Motley Fool

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

第 1 頁，共 2 頁

Standard BioTools Inc. (LAB)